Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353774 | 1.00 | NOTUM (0.44) | NOTUMHTR5AP2RX7PARP1PARP10 | |
| SCHEMBL2260714 | 0.88 | GRIA1 (0.41) | NOTUMHTR5ADRD2DRD3SRD5A1 | |
| SCHEMBL30634170 | 0.88 | GRIA1 (0.41) | NOTUMHTR5ADRD2DRD3SRD5A1 | |
| SCHEMBL15311783 | 0.83 | NISCH (0.42) | NOTUMPARP1PARP10PARP11BCHE | |
| SCHEMBL27380736 | 0.78 | HTR5A (0.38) | HTR5AP2RX7 | |
| SCHEMBL20539302 | 0.77 | NOTUM (0.47) | NOTUMPARP1PARP10PARP11BCHE | |
| SCHEMBL30916119 | 0.77 | NOTUM (0.47) | NOTUMPARP1PARP10PARP11BCHE | |
| SCHEMBL1031679 | 0.74 | NOTUM (0.48) | NOTUMP2RX7DRD2HTR7 | |
| SCHEMBL18689813 | 0.74 | NOTUM (0.44) | NOTUMPARP1PARP10PARP11DRD2 | |
| SCHEMBL326593 | 0.74 | PARP10 (0.56) | NOTUMPARP1PARP10PARP11BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229350-A | 4-fluoro-indoline compound and preparation method and application thereof | 曲阜师范大学 | 2023-12-15 | — | — | CN | claimed |
| CN-113788779-B | Acceptor-donating compound based on diphenyl sulfone and indole derivatives, and preparation method and application thereof | 太原理工大学 | 2023-09-15 | — | — | CN | claimed |
| CN-115353478-A | Preparation method of indole compound | 南京工业大学 | 2022-11-18 | — | — | CN | claimed |
| CN-113788779-A | A series of donor-acceptor type compounds based on diphenyl sulfone and indole derivatives, and preparation methods and applications thereof | 太原理工大学 | 2021-12-14 | — | — | CN | claimed |
| CN-112321478-A | Synthetic method of 4-fluoro-7-nitroindole or derivative thereof | 上海代为化学科技有限公司 | 2021-02-05 | — | — | CN | claimed |
| EP-4638442-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| CN-119968361-A | Compounds targeting p 53Y 220 mutants | 北京加科思新药研发有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119822910-A | Method for catalyzing heterogeneous reduction of nitrogen-containing heterocyclic compound by using magnesium metal | 延安大学 | 2025-04-15 | — | — | CN | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20080027122-A1 | Indole derivatives | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| WO-2008013322-A1 | 1- (-D-GLYCOPYRANOSYL) - 3 - (4-CYCLOPROPYLPHENYLMETHYL) - 4 - HALOGENO INDOLE DERIVATIVES AND USE THEREOF AS SGLT INHIBITORS. | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-31 | — | — | WO | disclosed |
| EP-1863798-A1 | INDOLE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007075895-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2006080577-A1 | INDOLE DERIVATIVES | TANABE SEIYAKU CO., LTD. (JP) | 2006-08-03 | — | — | WO | disclosed |
| US-20060100202-A1 | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1474403-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003053945-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027122-A1 | Indole derivatives | SLC5A1, SLC5A2, SLC5A11 | NOTUM 3579/4885HTR5A 116/4885P2RX7 2398/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | NOTUM 4541/4885HTR5A 4490/4885P2RX7 4455/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | NOTUM 2701/4885HTR5A 4206/4885P2RX7 4768/4885 |
| US-20060100202-A1 | Novel compounds | F12, REN, AVPR2 | NOTUM 2076/4885HTR5A 3021/4885P2RX7 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.